Flupen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flupen

Quick Facts

Property Description
Active ingredient Flucloxacillin (or Flucloxacillin sodium)
Form Capsule, Tablet, Powder for solution for injection
Pharmacological class Antibiotic (Penicillinase-resistant penicillin)
Common use Treating specific bacterial infections
Origin Semi-synthetic

What Type of Medicine is Flupen (Flucloxacillin)?

Flupen is a registered trade name for the medicine containing the active ingredient Flucloxacillin, a semi-synthetic antibiotic classified as a specialized penicillin used to combat susceptible bacterial infections. Its identity as a penicillinase-resistant penicillin is a critical distinction that indicates its utility against strains that would otherwise deactivate standard penicillins. Flucloxacillin's efficacy against bacteria that produce penicillinase is clinically recognized. This specialized structure protects the drug from the enzyme that destroys many other antibiotics. The medicine is categorized within the beta-lactam antibacterials family.


Composition and Available Pharmaceutical Forms

The core composition of this medicine is the single active ingredient, Flucloxacillin (often as the sodium salt), which is prepared for both oral and parenteral administration routes. For oral intake, the medicine is available in solid forms, such as capsules and tablets, or as a powder for oral solution, which is often formulated to be suitable for pediatric patients. For more immediate or systemic delivery, the drug is supplied as a sterile powder for solution for injection, allowing for administration via the intravenous or intramuscular routes following reconstitution with a suitable solvent. The availability of multiple pharmaceutical preparations, including those tailored for specific patient groups, ensures flexibility in delivery based on therapeutic need.


How Flucloxacillin’s Mechanism Affects Its General Purpose

The general purpose of the medicine is to decisively stop the progression of targeted bacterial infections via a direct bactericidal action. For instance, it is typically used in scenarios where staphylococcal skin and soft-tissue infections are suspected, such as cellulitis, due to the prevalence of resistant strains. Critically, its penicillinase-resistant nature means its core therapeutic utility is directed at eliminating penicillinase-producing staphylococci, thereby providing a reliable treatment option where the infection is known or suspected to be caused by these specific resistant strains.

What side effects are possible with Flupen?

Possible Side Effects and Safety Information

The safety profile of Flucloxacillin (Flupen) is officially documented by government regulatory bodies, detailing adverse reactions by their likelihood of occurrence and the body systems affected. These classifications are based on extensive clinical data and surveillance.

Adverse Reactions by Frequency

Classification Examples of Officially Documented Effects
Common Minor gastrointestinal disturbances (e.g., diarrhea).
Uncommon Dermatological reactions (e.g., rash, urticaria).
Very Rare Anaphylactic shock, severe hepatitis and cholestatic jaundice, severe skin reactions (SJS/TEN), and blood disorders.

Organ System Involvement and Serious Events

The most common adverse effects involve the Gastrointestinal System. However, the official safety documentation highlights the potential for very rare, but serious, reactions in the Hepatobiliary System (liver) and the Immune System (severe hypersensitivity).

Serious Adverse Reactions documented in regulatory sources include Anaphylactic Shock and Severe Hepatitis/Cholestatic Jaundice. Fatal outcomes have been reported in very rare cases, typically in patients with serious underlying conditions. Other documented serious events include Pseudomembranous Colitis and potentially life-threatening metabolic changes like High Anion Gap Metabolic Acidosis (HAGMA) and Hypokalaemia.

Safety Considerations for Specific Contexts

Certain factors are officially noted to affect the safety profile. Older adults (typically over 50 years of age) and patients receiving prolonged treatment (over 14 days) have a documented increased risk of hepatic reactions, which may have a delayed onset of up to two months post-treatment. Caution is also required for patients with renal or hepatic impairment, as these conditions can increase the risk of adverse events, such as neurological disorders (convulsions) with high parenteral doses in renal failure.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Flucloxacillin (Flupen) describe specific clinical manifestations and mandated emergency actions in the event of an overdose.

Documented Overdose Manifestations

Documented overdose presentations typically involve acute gastrointestinal distress, including nausea, vomiting, and diarrhoea. Risks of neurotoxicity may arise from very high doses, potentially manifesting as convulsions (fits), particularly in patients with pre-existing renal failure or impaired kidney function. High exposure may also lead to severe electrolyte imbalances, specifically Hypokalaemia (low potassium) and Hypernatraemia (high sodium). A specific risk of High Anion Gap Metabolic Acidosis (HAGMA) is officially noted when Flucloxacillin is co-ingested with paracetamol in at-risk patients, such as those with malnutrition or sepsis.

When Urgent Medical Help is Required

Official guidance mandates that immediate medical advice must be sought following any suspected overdose, even if the individual feels well. This urgent action is required due to the documented potential for delayed, serious consequences, including liver damage. Individuals must go immediately to the nearest hospital casualty department or contact the National Poisons Centre.

Supportive and Population-Specific Notes

Management is officially defined as symptomatic and supportive treatment, with continuous monitoring of electrolyte balance, blood counts, and renal function often recommended. It is documented that Flucloxacillin is not significantly removed by haemodialysis. Specific population concerns are noted, including the risk of kernicterus for newborns receiving high parenteral doses, and heightened neurotoxicity risk for those with kidney impairment.

Therapeutic Uses of Flupen

What Flupen Treats: Main Uses and Benefits

Flupen (Flucloxacillin) is applied across domains where additional symptomatic support is needed to treat specific bacterial infections, primarily those caused by susceptible Staphylococcus species. It is generally used for conditions characterized by periods of heightened symptoms related to localized inflammation.

The medicine is relevant for addressing bacterial strains known to exhibit resistance to certain other penicillin types. It helps address symptom clusters that may become intense or disruptive, such as intense redness, localized swelling, pus formation, and fever. It is relevant for easing conditions presenting with systemic or localized discomfort, including cellulitis, abscesses, impetigo, and certain serious infections like bacteremia, osteomyelitis, and endocarditis. This makes it commonly used when short-term symptomatic assistance is needed to support the process of managing the infectious agent. The medicine supports patients during difficult episodes by easing distress and contributes to improved day-to-day comfort during symptomatic periods.


Quick Fact: Symptomatic Relief for Staphylococcal Infections

Flupen is applied in clinical settings that involve acute or unstable symptom patterns, providing supportive relief when symptoms interfere with routine activities, such as those related to acute skin and soft tissue infections or surgical prophylaxis.

Eligibility and Restrictions for Use

The eligibility profile for Flupen (Flucloxacillin) is defined by regulatory bodies based on specific patient characteristics and medical history.

Use is Strictly Contraindicated in:

  • Patients with a documented history of hypersensitivity or allergy to Flucloxacillin or any other beta-lactam antibiotics, including penicillins.
  • Individuals with a previous history of Flucloxacillin-associated jaundice or other hepatic dysfunction.
  • Patients with a prior diagnosis of Acute Generalized Exanthematous Pustulosis (AGEP).

Use Requires Special Caution or Restriction in:

  • Newborns and infants, especially those with jaundice, due to the potential risk of hyperbilirubinemia or kernicterus.
  • Older adults (ge 50 years) and patients with serious underlying disease due to an increased risk of severe liver reactions.
  • Patients with severe renal failure (creatinine clearance <10 mL/min), which necessitates careful, conditional use and often requires dosage modification.
  • Pregnancy and Breastfeeding: Use is conditional and should occur only when the potential benefits strictly outweigh the potential risks, as trace amounts are excreted in breast milk.

This information strictly outlines the population groups permitted or restricted from using the medicine according to official regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Flupen (Flucloxacillin) outlines specific prohibitions and constraints related to co-administered substances, primarily based on pharmacokinetic and pharmacodynamic interactions.


Prohibited Combinations

Flucloxacillin is formally contraindicated in patients with a prior history of flucloxacillin-associated jaundice or hepatic dysfunction, as well as those with known hypersensitivity to beta-lactam antibiotics.


Exposure-Altering and Pharmacokinetic Interactions

Co-administration with Probenecid or Sulfinpyrazone is documented to decrease the renal tubular secretion of flucloxacillin, which delays excretion and increases the medicine’s plasma concentration. Conversely, flucloxacillin may reduce the excretion of Methotrexate, which raises the risk of Methotrexate toxicity.


Pharmacodynamic and Efficacy Interactions

Combining flucloxacillin with Paracetamol is officially associated with an increased risk of High Anion Gap Metabolic Acidosis (HAGMA), particularly in high-risk patients like those with severe renal impairment or sepsis. Additionally, the effectiveness of Voriconazole and oral contraceptives may be impaired.


Administration and Timing Constraints

Oral formulations must be taken on an empty stomach (at least 30 to 60 minutes before food or 2 hours after) because food reduces drug absorption. Parenteral administration must not be mixed with Aminoglycosides in a syringe or giving set due to physical incompatibility.

Mechanism of Action

Inhibition of Bacterial Cell Wall Construction

Flucloxacillin's mechanism involves the irreversible inhibition of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for building the rigid structural mesh of the cell wall. By blocking the final cross-linking reaction (transpeptidation), the drug causes the cell wall structure to become defective. The resulting failure to withstand internal osmotic pressure leads directly to the rupture and destruction (bactericidal lysis) of the susceptible bacterial cell.

Mechanism against beta-Lactamase

A key structural feature of Flucloxacillin is a specialized isoxazolyl side chain that provides steric hindrance. This shielding effect prevents the active beta-lactam core from being chemically degraded by beta-lactamase enzymes (penicillinase), which are produced by some bacterial strains. This structural feature confers resistance, allowing the drug to bind and inhibit the PBPs even when the bacterial enzyme is present. This maintains the anti-cell-wall activity against bacterial strains that produce this enzyme.

Mechanistic Limitation: Altered Targets

The mechanism fails when bacteria acquire genes to produce structurally different PBPs (e.g., PBP2a). This altered target has a significantly reduced affinity for Flucloxacillin. The failure of the drug to bind and inhibit the enzymes allows the bacterial cell wall synthesis pathway to remain functional, which prevents the drug from producing the lytic physiological effect.

Dosage and Administration Information

How to Use Flupen (Flucloxacillin)

This section describes the high-level principles for Flucloxacillin administration and dosing.


Administration and Dosing Principles

Category Administration Guidelines
Route of Administration The medicine is approved for Oral intake (capsules, solution) and Parenteral administration, including Intravenous (IV) and Intramuscular (IM) injection.
Standard Frequency Flucloxacillin is typically administered in divided doses, most commonly four times a day (QID), to maintain consistent systemic concentration.
Oral Intake Timing Oral forms must be taken on an empty stomach for optimal absorption, generally 30 minutes to one hour before a meal, or at least two hours after eating.
Standard Adult Dose Standard adult oral doses range from 250 mg to 500 mg. For severe or deep-seated infections, higher doses, such as 1 g to 2 g administered parenterally, may be required.
Typical Duration A standard course of treatment for most susceptible infections usually lasts 7 to 14 days, though severe conditions like endocarditis or osteomyelitis often require administration for several weeks or more.

Procedural and Population Constraints

Special Conditions: Parenteral forms, supplied as a powder, require reconstitution with an appropriate solvent before injection. The IV injection should be administered slowly, typically over a period of three to four minutes.

Dose Adjustment: Dose reduction or extension of the dosing interval is indicated for patients with severe renal impairment (creatinine clearance less than 10 mL/min). For pediatric patients, the dose is generally calculated based on body weight.

Missed Dose Protocol: If a dose is missed, it should be taken as soon as the patient remembers, but subsequent doses must be spaced out by at least four hours.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flupen


Evidence Base for Acute Skin and Soft-Tissue Infections

Flucloxacillin was studied for its use in treating acute, localized infections of the skin and soft tissues, such as cellulitis and erysipelas. The research base for this common use includes Randomized Controlled Trials (RCTs), systematic reviews, and observational studies that have included Flucloxacillin or followed its use in large patient groups. These trials primarily focused on short-term outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states. Researchers monitored whether patients achieved clinical resolution, which was often defined by doctors observing the resolution of signs like redness and swelling within an intermediate time frame, typically one to three weeks.

Studies reported measurements of changes observed in the signs of infection, and some trials described patterns in how symptoms evolved in the observed populations. However, the evidence quality varies across studies due to differences in how the infections were defined and measured. Follow-up durations were limited in many of these trials, and results often apply only to the populations studied, making it difficult to generalize.

Research Findings for Serious Bloodstream Infections

For more serious systemic or functional imbalance conditions, such as Staphylococcus aureus Bacteremia (SAB) (a type of bloodstream infection), research has explored Flucloxacillin's role. These studies primarily examined serious endpoints like all-cause mortality at 30 and 90 days, the duration of bacteremia, and the likelihood of infection recurrence. The data from these research scenarios show patterns related to mortality rates and time to fever resolution in cohorts treated with Flucloxacillin compared to cohorts treated with other standard anti-staphylococcal therapies. The collective evidence contributes to the broader evidence landscape, but uncertainty remains regarding its application across all specific clinical situations.

Frequently Asked Questions (FAQ)

Common questions about Flupen (FAQ)


Q: How long after starting Flupen might I notice a change?

Studies examining the use of Flupen for common acute skin infections have monitored when patients achieve clinical resolution. Evidence indicates that the resolution of signs like redness and swelling is often observed within an intermediate time frame, noted as one to three weeks after starting treatment. This information provides a general timeframe described in research, but individual response can vary.


Q: Are there any foods or drinks I should avoid while using Flupen?

Official information emphasizes that the oral forms of Flupen must be taken on an empty stomach to ensure optimal absorption. This is a core administration requirement to ensure the medicine works as intended, and full details on timing are provided in the official administration section. Outside of this timing constraint, the regulatory documents do not specify a list of specific foods or drinks that must be avoided.


Q: Can older people (seniors) use Flupen?

Official regulatory documents describe Flupen as being used by older adults. However, special caution is documented for people typically over 50 years of age, as this group has an increased risk of severe liver reactions. Dosage modification requirements are generally determined by specific co-existing health conditions, not age alone.


Q: Is Flupen a medicine that needs to be taken long-term?

The typical course of treatment for most susceptible infections is usually short-term, generally lasting 7 to 14 days. Official protocols for certain serious conditions, such as bone or heart lining infections, are documented to require administration for several weeks or more. The duration of use is determined by the specific condition being treated, as outlined in official protocols.


Q: Are there studies looking at the long-term effects of using Flupen?

Research studies examining Flucloxacillin have tended to focus on short- to intermediate-term outcomes related to infection resolution. While research follow-up is often limited, official safety information notes a documented heightened risk of hepatic reactions (liver issues) when the medicine is used for prolonged periods.


Q: Is Flupen prescribed for children or teenagers?

Yes, official administration guidelines include protocols for pediatric patients. However, official information describes the need for special caution in newborns and infants, particularly those with jaundice, due to a potential risk of hyperbilirubinemia, which relates to high bilirubin levels.


Q: Is Flupen intended to be a cure or a management tool?

The medicine’s mechanism of action is described as bactericidal, meaning it directly kills the susceptible bacteria by causing the breakdown of their cell walls. Its general purpose, as stated in official documents, is to decisively stop the progression of targeted bacterial infections. In this context, its action is directed toward clearing the infection.


Q: What is the typical time frame for the initial effects of Flupen to become stable?

For skin and soft-tissue infections, research protocols have described monitoring for the resolution of signs like redness and swelling within one to three weeks. This intermediate timeframe is what has been described in research that monitors for apparent stabilization. Individual patient experience and the type of infection being treated may lead to variations in this timeframe.


Q: Does the dose of Flupen need to be adjusted over time?

Official guidelines primarily mandate dose adjustment or extended dosing intervals for patients with severe renal impairment (kidney issues). Adjustments are also made based on body weight for pediatric patients. Outside of these specific population and health constraints, adjustments are determined by the prescribing professional based on official protocols.


Q: What is the primary way Flupen leaves the body (e.g., kidneys or liver)?

Official information indicates that Flucloxacillin is primarily eliminated from the body via the kidneys. This is supported by the regulatory requirement for dose reduction in patients with severe renal impairment to prevent the medicine's concentration from becoming too high. While the liver is associated with rare adverse reactions, the kidneys are identified as the primary route for excretion.


Q: Is it normal to feel a little dizzy when first starting Flupen?

Official safety documents list dizziness as a very rare or rare adverse effect associated with Flucloxacillin. While it is not a common side effect, its documented presence means it may occur. If this side effect is experienced, official information notes that caution is advised regarding activities requiring full concentration, such as driving.


Q: What is the risk of stopping Flupen suddenly?

Regulatory information notes that the risk associated with premature cessation of the medicine is that the underlying infection may not be fully cleared, potentially leading to a recurrence or worsening of the condition. Completion of the full treatment course is an established protocol to minimize this risk.


Q: Can I drive or operate machinery while taking Flupen?

Official labeling generally states that Flucloxacillin has no or negligible influence on a person's ability to drive or use machines. However, if side effects occur that could impair judgment, such as dizziness or feeling unwell, official information advises caution regarding driving or operating machinery.


Q: What should I do if a side effect of Flupen bothers me a lot?

Patient leaflets recommend speaking to a doctor or pharmacist immediately if you experience any side effects, especially if they are bothersome or severe. This allows for professional assessment and management of the reaction. This guidance includes any possible side effects that may not be explicitly listed in the patient information.


Q: Is there a generic version of Flupen available?

The active ingredient in Flupen is Flucloxacillin. Flucloxacillin is available under various trade names globally, such as Floxapen and Ladropen, and it is also marketed as a generic medicine. The availability of generic or branded versions depends on the region and local regulatory factors.


Q: Can Flupen make me feel tired or drowsy?

Drowsiness or tiredness is not typically listed in the official documents as one of the common side effects of Flupen. If light-headedness or fatigue is experienced, official information advises caution regarding activities requiring high levels of alertness.


Q: Are there certain medical tests I need to have while taking Flupen?

Official protocols require regular measurement of potassium levels for patients receiving high doses of the medication. Liver enzyme monitoring is also documented as necessary for some patients due to the risk of hepatic reactions. These tests are determined by the prescribing professional based on individual patient circumstances.


Q: What should I know about taking Flupen with alcohol?

Regulatory documents do not specify a direct, absolute prohibition against consuming alcohol while taking Flupen. The product label does not contain specific restrictions on alcohol. Any concerns should be directed to the prescribing professional.


Q: Are the side effects of Flupen permanent?

Official safety information generally indicates that most documented adverse reactions associated with Flucloxacillin are reversible upon discontinuation of the therapy. However, specific, serious events like liver reactions (jaundice) are documented to persist for some time after the medicine has been stopped.


Q: Does Flupen have a potential for dependence?

Official safety information states that Flucloxacillin is not known to be habit-forming or associated with a potential for dependence. It is categorized as an antibiotic, and its primary therapeutic action is to address bacterial infection.


Q: Are there different brand names for the same drug, Flupen?

Yes, Flupen is a trade name for the active ingredient Flucloxacillin. Globally, the same active ingredient is marketed under several other trade names, such as Floxapen and Ladropen, in addition to being available as a generic medicine.

How should Flupen be stored and disposed of?

How to Store and Dispose of Flupen (Flucloxacillin)

Official regulatory guidelines dictate specific conditions for storing and discarding Flucloxacillin to maintain its stability.

Storage Conditions

Flucloxacillin must generally be stored at ambient temperatures, not exceeding 25 C or 30 C, depending on the formulation. It is mandatory to store the medicine in the original package and in a dry place to protect it from light and moisture. For child safety, the medicine must be kept out of the sight and reach of children at all times. Specific preparations may have a limited stability, requiring use within 3 months of opening the foil pouch.

Disposal Instructions

Unused or expired Flucloxacillin must be discarded according to local requirements. Official regulatory instructions prohibit disposing of the medicine via wastewater or household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flupen found in:

A-Z Index: